| Furie, 2022 [27] |
Obinutuzumab |
A humanized type II anti-CD20 monoclonal antibody |
Obinutuzumab was administered as a blinded intravenous infusion of 1,000 mg on day 1 and weeks 2, 24, and 26 |
4 |
|
| Jayne, 2022 [28] |
Anifrolumab |
Type I interferon receptor antibody |
900 mg for the first three doses, 300 mg thereafter intravenously every 4 weeks for 48 weeks |
3 |
|
| Furie, 2020 [25] |
Belimumab |
A recombinant human IgG-1λ monoclonal antibody that inhibits B-cell-activating factor |
Patients received intravenous belimumab at a dose of 10 mg per kilogram of body weight |
4 |
|
| He, 2020 [26] |
Low-dose IL-2 |
Expansion of immune tolerance-inducing Treg cells and suppression of effector T cells |
IL-2 (1 million IU) was administered subcutaneously every other day for 2 weeks (seven injections), followed by a 2-week break, as one treatment cycle of 4 weeks |
3 |
|
| Zhang, 2015 [24] |
Rituximab |
A chimeric monoclonal antibody that depletes CD20+ B cells |
Patients received intravenous pulse dose of 375 2 mg/m2 at weeks 0, 2, 4, and 6 |
2 |
|
| ACCESS, 2014 [23] |
Abatacept |
A fusion protein comprising CTLA-4 linked to the Fc portion of IgG1 |
Treatment was initiated with monthly infusions of abatacept at doses (for <60 kg, 500 mg; for 60–100 kg, 750 mg; for 100 kg, 1 gm) |
3 |
|
| Furie, 2014 [22] |
Abatacept |
A fusion protein comprising CTLA-4 linked to the Fc portion of IgG1 |
Patients received abatacept 30 mg/kg on days 1, 15, 29, and 57, followed by abatacept approximating 10 mg/kg (weight tiered: 500 mg for patients weighing <60 kg, 750 mg for patients 60–100 kg, 1,000 mg for patients 100 kg) on days 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337 |
3 |
|
| Mysler, 2013 [21] |
Ocrelizumab |
A recombinant humanized monoclonal antibody that depletes CD20 B cells |
Patients received 400 mg or 1,000 mg ocrelizumab given as an intravenous infusion on days 1 and 15, followed by a single infusion at week 16 and every 16 weeks thereafter |
3 |
|
| Rovin, 2012 [20] |
Rituximab |
A chimeric monoclonal antibody that depletes CD20+ B cells |
Patients received rituximab 1,000 mg administered intravenously on days 1, 15, 168, and 182 |
3 |
